MediciNova, Inc. announced the successful completion of patient enrollment for its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS).
The trial achieved its target enrollment, with a total of 234 patients randomized across multiple sites in the US and Canada. This milestone signifies a critical step forward in the development of MN-166.
Dr. Yuichi Iwaki, MediciNova President and CEO, stated that reaching the target enrollment allows the company to move confidently into the next phase of the trial. This brings MediciNova closer to understanding the potential impact of MN-166 for patients suffering from ALS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.